Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

Press release – No. 5 / 2024

Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, President and CEO, will participate in fireside chats at the following healthcare investor conferences in June:

  • Jefferies Global Healthcare Conference, June 4-6 in New York City

Wednesday, June 5 at 10:00 a.m. ET (4:00 p.m. CET)

A webcast of the fireside chat will be available at https://wsw.com/webcast/jeff302/register.aspx?conf=jeff302&page=zeal&url=https://wsw.com/webcast/jeff302/zeal/1839808 and accessible through the Events page in the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/ where a replay will also be archived after the fireside chat.

  • Goldman Sachs 45th Annual Global Healthcare Conference, June 10-13 in Miami

Wednesday, June 12 at 4:00 p.m. ET (10:00 p.m. CET)

A webcast of the fireside chat will be available at https://event.webcasts.com/starthere.jsp?ei=1672947&tp_key=a29a9e2b8f&tp_special=8 and accessible through the Events page in the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/ where a replay will also be archived after the fireside chat.

# # #

About Zealand Pharma

Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contacts:

Adam Lange (Investors)
Investor Relations Officer
Zealand Pharma
akl@zealandpharma.com
 
Anna Krassowska, PhD (Investors and Media)
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
ank@zealandpharma.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.